Halozyme Therapeutics Inc
NASDAQ:HALO
Halozyme Therapeutics Inc
NASDAQ:HALO
Price:
49
USD
7.22%
Market Closed
Market Cap:
6.2B
USD
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
HALO Alert
Halozyme Therapeutics Inc
49
+3.3 (+7.22%)
| 52 Week Range |
33.68
64.42
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Halozyme Therapeutics Inc
Income Statement
Earnings Waterfall
Halozyme Therapeutics Inc
Halozyme Therapeutics Inc
|
Revenue
|
947.4m
USD
|
|
Cost of Revenue
|
-169.7m
USD
|
|
Gross Profit
|
777.7m
USD
|
|
Operating Expenses
|
-300.7m
USD
|
|
Operating Income
|
477m
USD
|
|
Other Expenses
|
-84.5m
USD
|
|
Net Income
|
392.5m
USD
|
Income Statement
Halozyme Therapeutics Inc
Halozyme Therapeutics Inc
Currency: USD
| Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||||||||||||||
| Revenue |
58
N/A
|
75
+31%
|
82
+9%
|
107
+30%
|
113
+6%
|
135
+19%
|
159
+18%
|
149
-6%
|
160
+7%
|
147
-8%
|
134
-9%
|
134
+0%
|
166
+24%
|
317
+91%
|
318
+0%
|
319
+0%
|
281
-12%
|
152
-46%
|
178
+17%
|
182
+2%
|
202
+11%
|
196
-3%
|
164
-16%
|
181
+10%
|
200
+11%
|
268
+34%
|
331
+24%
|
413
+25%
|
463
+12%
|
443
-4%
|
472
+6%
|
488
+3%
|
581
+19%
|
660
+14%
|
705
+7%
|
774
+10%
|
781
+1%
|
829
+6%
|
863
+4%
|
873
+1%
|
947
+8%
|
|
| Gross Profit | ||||||||||||||||||||||||||||||||||||||||||
| Cost of Revenue |
(20)
|
(23)
|
(24)
|
(26)
|
(27)
|
(29)
|
(31)
|
(31)
|
(34)
|
(33)
|
(33)
|
(32)
|
(32)
|
(31)
|
(27)
|
(20)
|
(12)
|
(10)
|
(12)
|
(13)
|
(34)
|
(46)
|
(47)
|
(51)
|
(34)
|
(43)
|
(56)
|
(73)
|
(86)
|
(81)
|
(79)
|
(90)
|
(119)
|
(139)
|
(159)
|
(175)
|
(182)
|
(192)
|
(186)
|
(175)
|
(170)
|
|
| Gross Profit |
37
N/A
|
53
+41%
|
58
+11%
|
81
+39%
|
86
+6%
|
106
+23%
|
128
+21%
|
118
-8%
|
126
+7%
|
114
-10%
|
101
-11%
|
102
+1%
|
134
+32%
|
286
+112%
|
291
+2%
|
300
+3%
|
269
-10%
|
142
-47%
|
166
+17%
|
169
+2%
|
168
-1%
|
150
-11%
|
118
-22%
|
130
+10%
|
166
+28%
|
224
+35%
|
275
+23%
|
339
+23%
|
377
+11%
|
362
-4%
|
392
+8%
|
397
+1%
|
462
+16%
|
521
+13%
|
547
+5%
|
599
+10%
|
599
0%
|
637
+6%
|
677
+6%
|
698
+3%
|
778
+11%
|
|
| Operating Income | ||||||||||||||||||||||||||||||||||||||||||
| Operating Expenses |
(118)
|
(116)
|
(110)
|
(114)
|
(123)
|
(133)
|
(158)
|
(174)
|
(182)
|
(197)
|
(196)
|
(200)
|
(202)
|
(204)
|
(206)
|
(210)
|
(213)
|
(211)
|
(209)
|
(206)
|
(204)
|
(218)
|
(192)
|
(160)
|
(131)
|
(80)
|
(77)
|
(78)
|
(101)
|
(86)
|
(90)
|
(136)
|
(192)
|
(231)
|
(304)
|
(296)
|
(284)
|
(297)
|
(298)
|
(296)
|
(301)
|
|
| Selling, General & Administrative |
(37)
|
(36)
|
(35)
|
(36)
|
(38)
|
(40)
|
(41)
|
(43)
|
(44)
|
(46)
|
(48)
|
(50)
|
(51)
|
(54)
|
(55)
|
(56)
|
(58)
|
(61)
|
(65)
|
(68)
|
(71)
|
(77)
|
(72)
|
(66)
|
(59)
|
(46)
|
(44)
|
(46)
|
(47)
|
(50)
|
(52)
|
(78)
|
(99)
|
(122)
|
(147)
|
(147)
|
(148)
|
(149)
|
(147)
|
(144)
|
(150)
|
|
| Research & Development |
(81)
|
(80)
|
(75)
|
(78)
|
(85)
|
(93)
|
(117)
|
(131)
|
(137)
|
(151)
|
(148)
|
(150)
|
(151)
|
(151)
|
(152)
|
(154)
|
(155)
|
(150)
|
(144)
|
(137)
|
(132)
|
(141)
|
(120)
|
(95)
|
(72)
|
(34)
|
(33)
|
(32)
|
(33)
|
(36)
|
(39)
|
(46)
|
(54)
|
(67)
|
(73)
|
(77)
|
(78)
|
(76)
|
(77)
|
(79)
|
(80)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(11)
|
(39)
|
(43)
|
(61)
|
(67)
|
(58)
|
(71)
|
(71)
|
(71)
|
(71)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(21)
|
0
|
0
|
0
|
0
|
0
|
(23)
|
(5)
|
0
|
0
|
(3)
|
(3)
|
0
|
|
| Operating Income |
(80)
N/A
|
(63)
+22%
|
(52)
+18%
|
(33)
+37%
|
(37)
-13%
|
(28)
+25%
|
(30)
-8%
|
(56)
-87%
|
(55)
+1%
|
(83)
-51%
|
(95)
-14%
|
(98)
-4%
|
(68)
+31%
|
81
N/A
|
85
+5%
|
90
+6%
|
57
-37%
|
(69)
N/A
|
(43)
+38%
|
(37)
+14%
|
(36)
+3%
|
(68)
-90%
|
(74)
-9%
|
(30)
+59%
|
35
N/A
|
144
+317%
|
198
+37%
|
262
+32%
|
276
+5%
|
276
0%
|
302
+10%
|
262
-13%
|
270
+3%
|
289
+7%
|
243
-16%
|
303
+25%
|
315
+4%
|
340
+8%
|
379
+12%
|
402
+6%
|
477
+19%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
| Interest Income Expense |
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(7)
|
(11)
|
(15)
|
(19)
|
(20)
|
(20)
|
(20)
|
(19)
|
(18)
|
(16)
|
(13)
|
(11)
|
(8)
|
(6)
|
(4)
|
(5)
|
(6)
|
(10)
|
(13)
|
(15)
|
(14)
|
(12)
|
(9)
|
(6)
|
(6)
|
(9)
|
(14)
|
(16)
|
(16)
|
(14)
|
(6)
|
(2)
|
(0)
|
1
|
3
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(21)
|
(21)
|
0
|
(21)
|
(2)
|
(20)
|
(23)
|
(25)
|
0
|
0
|
(4)
|
(3)
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
13
|
13
|
13
|
13
|
0
|
|
| Pre-Tax Income |
(85)
N/A
|
(68)
+20%
|
(57)
+17%
|
(38)
+34%
|
(42)
-11%
|
(32)
+23%
|
(37)
-15%
|
(67)
-80%
|
(70)
-5%
|
(102)
-46%
|
(115)
-13%
|
(119)
-3%
|
(88)
+26%
|
62
N/A
|
67
+9%
|
75
+11%
|
44
-42%
|
(80)
N/A
|
(51)
+36%
|
(43)
+16%
|
(40)
+7%
|
(72)
-83%
|
(80)
-11%
|
(40)
+50%
|
22
N/A
|
129
+499%
|
164
+26%
|
229
+40%
|
267
+16%
|
249
-7%
|
295
+19%
|
233
-21%
|
233
0%
|
249
+7%
|
227
-9%
|
290
+28%
|
318
+10%
|
348
+10%
|
392
+13%
|
417
+6%
|
480
+15%
|
|
| Net Income | ||||||||||||||||||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
1
|
1
|
2
|
2
|
(1)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
(1)
|
(1)
|
142
|
154
|
140
|
133
|
(22)
|
(47)
|
(45)
|
(56)
|
(64)
|
(67)
|
(73)
|
(79)
|
(88)
|
|
| Income from Continuing Operations |
(85)
|
(68)
|
(57)
|
(38)
|
(42)
|
(32)
|
(37)
|
(67)
|
(71)
|
(103)
|
(116)
|
(120)
|
(88)
|
63
|
68
|
76
|
46
|
(80)
|
(51)
|
(43)
|
(40)
|
(72)
|
(80)
|
(40)
|
22
|
129
|
163
|
229
|
409
|
403
|
435
|
366
|
211
|
202
|
182
|
234
|
254
|
282
|
319
|
337
|
392
|
|
| Net Income (Common) |
(85)
N/A
|
(68)
+20%
|
(57)
+17%
|
(38)
+34%
|
(42)
-11%
|
(32)
+23%
|
(37)
-15%
|
(67)
-81%
|
(71)
-7%
|
(103)
-44%
|
(116)
-13%
|
(120)
-3%
|
(88)
+26%
|
63
N/A
|
68
+8%
|
76
+12%
|
46
-40%
|
(80)
N/A
|
(51)
+36%
|
(43)
+16%
|
(40)
+7%
|
(72)
-81%
|
(80)
-11%
|
(40)
+50%
|
22
N/A
|
129
+500%
|
163
+26%
|
229
+40%
|
409
+79%
|
403
-2%
|
435
+8%
|
366
-16%
|
211
-42%
|
202
-4%
|
182
-10%
|
234
+29%
|
254
+9%
|
282
+11%
|
319
+13%
|
337
+6%
|
392
+16%
|
|
| EPS (Diluted) |
-0.7
N/A
|
-0.56
+20%
|
-0.45
+20%
|
-0.3
+33%
|
-0.33
-10%
|
-0.25
+24%
|
-0.3
-20%
|
-0.53
-77%
|
-0.57
-8%
|
-0.81
-42%
|
-0.91
-12%
|
-0.89
+2%
|
-0.61
+31%
|
0.45
N/A
|
0.47
+4%
|
0.53
+13%
|
0.31
-42%
|
-0.56
N/A
|
-0.35
+38%
|
-0.29
+17%
|
-0.27
+7%
|
-0.5
-85%
|
-0.58
-16%
|
-0.28
+52%
|
0.16
N/A
|
0.91
+469%
|
1.09
+20%
|
1.56
+43%
|
2.79
+79%
|
2.74
-2%
|
3.07
+12%
|
2.57
-16%
|
1.51
-41%
|
1.44
-5%
|
1.3
-10%
|
1.75
+35%
|
1.89
+8%
|
2.1
+11%
|
2.47
+18%
|
2.6
+5%
|
3.02
+16%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
